Perrigo announces FDA final approval for AB rated generic version of Voltaren® gel 1%
Perrigo announced its partner received final approval from the FDA for its AB rated ANDA referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days.
May 21, 2019